Label: LACTULOSE solution
0121-0873-16, view more0121-0873-32, 0121-0873-40, 0121-1746-00, 0121-1746-06, 0121-1746-30, 0121-1746-40
- Packager: Pharmaceutical Associates, Inc.
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
Drug Label Information
Updated December 21, 2022
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
- SPL UNCLASSIFIED SECTION
Lactulose is a synthetic disaccharide in solution form for oral administration. Each 15 mL of Lactulose Solution contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose, and 1.2 g or less of other sugars).
Lactulose is a colonic acidifier which promotes laxation.
The chemical name for lactulose is 4-0-ß-D-galactopyranosyl-D-fructofuranose. It has the following structural formula:
The molecular weight is 342.30. It is freely soluble in water.
Lactulose is poorly absorbed from the gastrointestinal tract, and no enzyme capable of hydrolysis of this disaccharide is present in human gastrointestinal tissue. As a result, oral doses of lactulose solution reach the colon virtually unchanged. In the colon, lactulose is broken down primarily to lactic acid, and also to small amounts of formic and acetic acids, by the action of colonic bacteria, which results in an increase in osmotic pressure and slight acidification of the colonic contents. This in turn causes an increase in stool water content and softens the stool.
Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be slow, 24 to 48 hours may be required to produce the desired bowel movement.
Lactulose solution given orally to man and experimental animals resulted in only small amounts reaching the blood.
Urinary excretion has been determined to be 3% or less and is essentially complete within 24 hours.
- INDICATIONS AND USAGE
A theoretical hazard may exist for patients being treated with lactulose solution who may be required to undergo electrocautery procedures during proctoscopy or colonoscopy. Accumulation of H 2 gas in significant concentration in the presence of an electrical spark may result in an explosive reaction. Although this complication has not been reported with lactulose, patients on lactulose therapy undergoing such procedures should have a thorough bowel cleansing with a non-fermentable solution. Insufflation of CO 2 as an additional safeguard may be pursued but is considered to be a redundant measure.
Since lactulose solution contains galactose (less than1.6 g/15 mL) and lactose (less than 1.2 g/15 mL), it should be used with caution in diabetics.
Information for Patients
In the event that an unusual diarrheal condition occurs, contact your physician.
Elderly, debilitated patients who receive lactulose solution for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically.
Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose solution.
Carcinogenesis, Mutagenesis, Impairment of Fertility
There are no known human data on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility.
There are no known animal data on long-term potential for mutagenicity.
Administration of lactulose solution in the diet of mice for 18 months in concentrations of 3 and 10 percent (v/w) did not produce any evidence of carcinogenicity.
In studies in mice, rats, and rabbits, doses of lactulose solution up to 6 or 12 mL/kg/day produced no deleterious effects in breeding, conception, or parturition.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lactulose solution is administered to a nursing woman.
Precise frequency data are not available.
Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia, and hypernatremia.
Nausea and vomiting have been reported.
To report SUSPECTED ADVERSE REACTIONS, contact Pharmaceutical Associates, Inc. at 1-800-845-8210 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Signs and Symptoms
There have been no reports of accidental overdosage. In the event of overdosage, it is expected that diarrhea and abdominal cramps would be the major symptoms. Medication should be terminated.
Oral LD 50
The acute oral LD 50 of the drug is 48.8 mL/kg in mice and greater than 30 mL/kg in rats.
DOSAGE AND ADMINISTRATION
The usual dose is 1 to 2 tablespoonfuls (15 to 30 mL, containing 10 g to 20 g of lactulose) daily. The dose may be increased to 60 mL daily if necessary. Twenty-four to 48 hours may be required to produce a normal bowel movement.
Note: Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water or milk.
Lactulose Solution, USP 10 g/15 mL is supplied as:
NDC 0121-0873-08: 8 fl oz (237 mL) bottles
NDC 0121-0873-16: 16 fl oz (473 mL) bottles
NDC 0121-0873-32: 32 fl oz (946 mL) bottles
NDC 0121-0873-15: 15 mL unit dose cup. Case contains 40 unit dose cups of 15 mL (NDC 0121-0873-40), packaged in 4 trays of 10 unit-dose cups each and 96 unit dose cups of 15 mL (NDC 0121-0873-06) packaged in a carton of 16 unit dose cups each.
NDC 0121-1746-30: 30 mL unit dose cup. Case contains 40 unit dose cups of 30 mL (NDC 0121-1746-40), packaged in 4 trays of 10 unit-dose cups each, 100 unit dose cups of 30 mL (NDC 0121-1746-00), packaged in 10 trays of 10 unit-dose cups each and 96 unit dose cups of 30 mL (NDC 0121-1746-06) packaged in a carton of 16 unit dose cups each.
Store at controlled room temperature, 20°to 25°C (68° to 77°F). [See USP] Do not freeze.
Under recommended storage conditions, a normal darkening of color may occur. Such darkening is characteristic of sugar solutions and does not affect therapeutic action. Prolonged exposure to temperatures above 30°C (86°F) or to direct light may cause extreme darkening and turbidity which may be pharmaceutically objectionable. If this condition develops, do not use.
Prolonged exposure to freezing temperatures may cause change to a semisolid, too viscous to pour. Viscosity will return to normal upon warming to room temperature.
Dispense in original container or in a tight, light-resistant container with a child-resistant closure.
To the Pharmacist: When ordering this product, include the NDC number in the description.
- MANUFACTURED BY
Reproduction studies have been performed in mice, rats, and rabbits at doses up to 3 or 6 times the usual human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to lactulose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label
Lactulose Solution USP
10 g/15 mL
Each 15 mL contains: 10 g lactulose (and less than
1.6 g galactose, less than 1.2 g lactose, and 1.2 g or
less of other sugars).
Dispense in original container or tight, light-resistant
container with a child-resistant closure.
To the Pharmacist: When ordering this product,
include the product number (or NDC) in the
16 fl oz (473 mL)
Greenville, SC 29605
- PRINCIPAL DISPLAY PANEL - 15 mL Cup Lid - NDC 0121-0873-15
- PRINCIPAL DISPLAY PANEL - 30 mL Cup Lid - NDC 0121-1746-30
INGREDIENTS AND APPEARANCE
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0121-0873 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LACTULOSE (UNII: 9U7D5QH5AE) (LACTULOSE - UNII:9U7D5QH5AE) LACTULOSE 10 g in 15 mL Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:0121-0873-08 237 mL in 1 BOTTLE; Type 0: Not a Combination Product 12/03/2019 2 NDC:0121-0873-16 473 mL in 1 BOTTLE; Type 0: Not a Combination Product 12/03/2019 3 NDC:0121-0873-32 946 mL in 1 BOTTLE; Type 0: Not a Combination Product 12/03/2019 4 NDC:0121-0873-40 4 in 1 CASE 12/03/2019 4 10 in 1 TRAY 4 NDC:0121-0873-15 15 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product 5 NDC:0121-0873-06 6 in 1 CASE 12/03/2019 5 16 in 1 CARTON 5 15 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA074623 12/03/2019 LACTULOSE
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0121-1746 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LACTULOSE (UNII: 9U7D5QH5AE) (LACTULOSE - UNII:9U7D5QH5AE) LACTULOSE 20 g in 30 mL Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:0121-1746-40 4 in 1 CASE 12/03/2019 1 10 in 1 TRAY 1 NDC:0121-1746-30 30 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product 2 NDC:0121-1746-00 10 in 1 CASE 12/03/2019 2 10 in 1 TRAY 2 30 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product 3 NDC:0121-1746-06 6 in 1 CASE 12/03/2019 3 16 in 1 CARTON 3 30 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA074623 12/03/2019 Labeler - Pharmaceutical Associates, Inc. (044940096) Establishment Name Address ID/FEI Business Operations Pharmaceutical Associates, Inc. 097630693 manufacture(0121-0873, 0121-1746)